SNP microarray: A comprehensive guide to genotyping, data and discovery

In the expanding world of genetics, the SNP microarray stands out as a workhorse for large-scale genotyping. This technology, often simply described as a SNP array or genotyping array, enables researchers to assay hundreds of thousands to millions of single nucleotide polymorphisms (SNPs) across the genome. The result is a rich dataset that supports genome-wide association studies, population genetic analyses, pharmacogenomics, and much more. This guide explains what a SNP microarray is, how it works, the landscapes of platforms and applications, and what researchers should consider when planning and interpreting SNP microarray experiments.

What is a SNP microarray?

A SNP microarray is a dedicated DNA microarray designed to detect known SNPs across the genome. Each feature on the array corresponds to a specific SNP locus, with probes engineered to distinguish the two or more possible alleles at that position. When a laboratory uses a SNP microarray, the resulting data comprise genotype calls for each SNP in each sample, usually expressed as AA, AB, or BB, depending on the allelic composition detected at that locus. In practice, the technology is also exploited for copy number variation detection and for deriving ancestry information, given its dense genotype data across the genome.

Historically, SNP microarrays have provided a cost-effective alternative to sequencing for large cohorts. While next-generation sequencing (NGS) can capture novel or rare variants, SNP arrays excel at robust, scalable genotyping of common variants. In addition, arrays often support downstream analyses such as imputation to infer untyped SNPs using reference panels, enhancing genomic coverage beyond the directly measured sites.

How does a SNP microarray work?

Although the underlying chemistry varies slightly between platforms, the core workflow of a SNP microarray is generally as follows. A sample of DNA is prepared and fragmented, and then fluorescently labelled so that its SNP-containing fragments can be detected after hybridisation to the array. The array itself is a solid substrate, typically a glass slide or silicon chip, decorated with an immense number of allele-specific probes. Each probe is complementary to one allele at a given SNP locus. When the labelled DNA binds to the correct probes, a detection system (often fluorescence) signals the presence of a particular allele. Data analysis software then translates signal intensities into genotype calls for each SNP in each sample.

The beauty of SNP microarrays lies in the precision of probe design and the robustness of the clustering algorithms that assign genotypes. Modern platforms include stringent quality controls and extensive annotation of SNPs, including their chromosomal location, allele frequencies in various populations, and known implications for traits or diseases.

Probe design, density and SNP coverage

Two critical factors shape a SNP microarray’s usefulness: probe design and SNP density. Probes are crafted to maximise specific binding to one allele while minimising cross-hybridisation. The density—often described as the number of SNPs probed per sample—determines how comprehensively the genome is surveyed. Higher density arrays enable finer resolution for association analyses and CNV detection, but come with higher costs and larger data volumes. Researchers typically select arrays with densities aligned to their study goals, population focus, and budget.

Platforms and technology

Several major platforms dominate the SNP microarray landscape, each with its own strengths. While the core principle remains the same, differences in SNP content, density, probe chemistry and data processing lead to distinct performance profiles. Here is a snapshot of the landscape you might encounter in contemporary lab settings.

Illumina-style SNP microarrays

Illumina is renowned for its Infinium family of SNP arrays. These platforms use optical–electronic detection to read out genotype signals, with extensive software support for data QC and analysis. Infinium arrays are popular for large-scale association studies due to their high call rates, robust reproducibility, and well-documented imputation performance. The associated software ecosystem, including GenomeStudio for initial analysis and imputation pipelines, makes Illumina-based SNP microarrays a common choice in academic and clinical research.

Affymetrix/Thermo Fisher-style SNP arrays

Affymetrix, now under the Thermo Fisher umbrella, offers Axiom arrays and related technologies. Similar in purpose to Infinium arrays, Axiom platforms are prized for their extensive SNP content and flexibility for customised designs. Researchers select SNP microarrays on this platform when specific population representations or custom SNP panels are required. Like Illumina, robust quality control and downstream analysis tools are essential components of the workflow.

Comparing platforms: what to consider

• Population representation: Arrays are often designed with particular populations in mind; ascertainment bias can influence the ability to detect associations in non-target populations.
• SNP density and genome coverage: Higher density enhances GWAS power and CNV detection but increases costs and data handling demands.
• Genotype call quality and reproducibility: Platforms differ in call rates, autoflagged samples, and batch effects; these metrics are crucial for reliable results.
• Imputation performance: A strong reference panel increases imputation accuracy, expanding the effective genome coverage beyond directly genotyped SNPs.
• Analytical compatibility: Availability of well-supported software pipelines for QC, imputation, association testing and visualization matters for efficiency and reproducibility.

Applications of SNP microarray

The reach of the SNP microarray spans multiple domains, from fundamental research to translational science. Below are the principal application areas where SNP microarrays have made a lasting impact.

Genome-wide association studies (GWAS)

GWAS remains one of the primary drivers for the use of SNP microarrays. By genotyping hundreds of thousands to millions of SNPs across large cohorts, researchers can identify genetic variants associated with diseases, traits, or responses to therapy. The strength of SNP microarrays in GWAS lies in their scalability and the maturity of statistical methods for association testing, population stratification correction, and meta-analysis across studies.

Population genetics and ancestry inference

The genome-wide genotype data generated by SNP microarrays empower analyses of population structure, historical demography and admixture. Researchers can reconstruct ancestral lineages, estimate migration patterns, and explore fine-scale population differentiation. In commercial or clinical contexts, ancestry information can influence interpretability of results and the selection of appropriate reference panels for imputation.

Pharmacogenomics and personalised medicine

SNP microarrays contribute to pharmacogenomic research by identifying variants that predict drug response, metabolism, or toxicity. In research settings and some clinical programmes, genotype data inform therapeutic choices and risk assessment for adverse reactions. The integration of SNP microarray data with electronic health records and clinical phenotypes is an important frontier in personalised medicine.

Copy number variation and structural insights

Beyond single base changes, SNP microarrays provide CNV information through analysis of signal intensity and allelic imbalance. While dedicated CNV platforms or sequencing techniques may offer higher resolution, SNP microarrays remain a practical tool for detecting larger CNVs and for cross-cohort comparisons where CNV patterns contribute to disease risk or phenotypic variation.

Rare variant discovery and imputation-enabled analyses

Although SNP arrays target common or well-characterised variants, their genotype data can be augmented by imputation to infer untyped SNPs. Imputation leverages reference panels such as the 1000 Genomes Project or population-specific resources to fill in the gaps, increasing the number of testable variants and enhancing discovery potential in GWAS and related studies.

SNP microarray versus alternative technologies

Choosing between a SNP microarray and other genomic technologies depends on project goals, budget, and the desired resolution. Here are common considerations when weighing SNP microarray against alternatives like whole-genome sequencing (WGS) or targeted sequencing.

Compared with next-generation sequencing (NGS)

NGS provides base-level resolution and discovers novel variants, including rare and structural changes. SNP microarray, by contrast, offers high-throughput, cost-effective genotyping of predefined SNPs across many samples. For large cohorts focused on common variant associations, arrays remain cost-efficient. For discovery of novel variants or detailed rare variant analyses, sequencing is more informative, albeit more expensive at scale.

Compared with array CGH and other CNV-focused platforms

Array comparative genomic hybridisation (array CGH) and SNP arrays both detect copy number changes, but array CGH is optimised for CNV discovery with continuous copy number measurements, while SNP microarrays provide discrete genotype calls with additional SNP information for association studies or imputation.

Clinical utility and regulatory considerations

In clinical genetics, SNP microarray data may support diagnostic workflows, pharmacogenomics, or ancestry-informed reporting. Regulatory requirements and standard-of-care guidelines influence assay selection, validation, and interpretation frameworks. Clinical SNP microarray tests typically emphasise reproducibility, clear reporting of CNVs and clinically actionable variants, and robust data privacy safeguards.

Data analysis, quality control and interpretation

Effective analysis of SNP microarray data hinges on rigorous quality control, thoughtful statistical analysis, and careful interpretation. The following components are central to sound workflows.

Initial data processing and genotype calling

Raw fluorescence signals must be translated into genotype calls through clustering algorithms. This step requires careful inspection of cluster plots, sample-level metrics, and probe-level performance. Poor clustering can lead to miscalls, especially for rare variants or poorly performing SNPs. Quality control at this stage helps prevent downstream bias in association results.

Sample and SNP level quality control

Typical QC metrics include sample call rates, heterozygosity, relatedness checks, sex concordance, and plate or batch effects. SNP-level QC assesses call rate per SNP, deviation from Hardy–Weinberg equilibrium in control populations, minor allele frequency thresholds, and differential missingness. Outlier samples or SNPs are flagged and may be excluded from analyses.

Imputation and data enrichment

Imputation fills in untyped SNPs using reference panels. This step increases variant density and can improve the power of GWAS. The imputation process requires pre-phasing, a carefully curated reference panel representative of the study population, and post-imputation quality control to filter variants by imputation quality scores.

Statistical analyses and interpretation

Association analyses model the relationship between SNP genotypes and phenotypes, accounting for population structure and relatedness. Meta-analyses across cohorts enhance discovery. Interpreting results involves assessing effect sizes, p-values, and potential functional implications, as well as integrating eQTL data, regulatory annotations, and haplotype context to prioritise candidate variants.

Quality control best practices for SNP microarray experiments

To obtain reliable, reproducible results from a SNP microarray, follow stringent quality control practices from design to data analysis. Some guidelines include:

• Plan with population-specific considerations in mind to minimise ascertainment bias.
• Use high-quality DNA with adequate concentration and integrity; degraded samples compromise call rates.
• Incorporate technical replicates and run controls to monitor assay performance.
• Monitor plate-by-plate and batch effects; randomise sample placement when possible.
• Apply robust QC thresholds for sample call rate (often >98–99%) and SNP call rate (also typically >98–99%).
• Perform sex-checks to confirm sample annotations and detect potential sample swaps.
• Validate key findings with independent assays or replication cohorts where feasible.

Practical considerations for laboratories adopting SNP microarray

For laboratories weighing the adoption of SNP microarray technology, several practical considerations matter. Budget, personnel expertise, data storage and computational resources, and timelines shape decision-making. The following are common practicalities to address before procurement and implementation:

• Cost per sample versus projected study size and density requirements.
• Platform selection aligned with population representation and intended analyses.
• Availability of on-site facilities or access to outsourced services for sample preparation and data processing.
• Readiness of data analysis pipelines, including quality control, imputation, and association analysis workflows.
• Ethical considerations and consent provisions for handling genotype data, with attention to privacy and data sharing policies.

Ethical, legal and social considerations

Genomic data, including SNP microarray genotypes, raise important ethical and legal questions. In research contexts, informed consent should cover data sharing, potential re-use of data for secondary analyses, and the possibility of re-identification through genotype information. Data governance frameworks and institutional review processes guide responsible data management, access control, and compliance with applicable laws and regulations.

Future directions for SNP microarray technology

Even as sequencing technologies advance, SNP microarrays have a continuing role due to their cost-effectiveness for large cohorts and their well-established analytical ecosystems. Anticipated developments include denser SNP content for more precise imputation, improved cross-population panels to reduce ascertainment bias, and enhanced integration with multi-omics data. Hybrid approaches combining SNP microarray data with targeted sequencing or functional annotations are likely to become more common, enabling richer, actionable insights from genetic studies.

Case studies and practical takeaways

Consider a few practical scenarios to illustrate how a SNP microarray strategy can be optimally deployed:

• A large cardiometabolic GWAS aiming to identify common risk variants may benefit from a high-density SNP microarray with proven imputation performance in diverse populations, followed by meta-analysis across cohorts to maximise power.
• A pharmacogenomics programme seeking to predict drug response could focus on SNP panels known to influence metabolism, with targeted follow-up sequencing for rare variants where needed.
• A population genetics project investigating ancestry and admixture might prioritise array content that provides robust coverage across the populations of interest, complemented by imputation and haplotype analyses.
• Clinical diagnostics focusing on copy number variation may incorporate SNP microarray data alongside other CNV-detection methods, ensuring comprehensive reporting of clinically actionable findings.

Putting it all together: planning a SNP microarray study

Effective planning begins with a clear research question, a defined population, and a realistic budget. The planning phase should address platform selection, SNP density, array content (including any customised SNP panels), the necessity for imputation, and data management plans. The subsequent lab work, QC steps, and statistical analysis pipelines should be designed to maintain high data quality and reproducibility. Finally, transparent reporting of methods and results, with sufficient detail to enable replication, strengthens the impact of your SNP microarray study.

In summary: why a SNP microarray remains a cornerstone of genomic research

The SNP microarray combines scalability, affordability and robust analytical support. It remains a cornerstone technology for large-scale genetic studies, enabling researchers to dissect the genetic architecture of complex traits, understand population history, and inform personalised medicine strategies. While sequencing continues to push the boundaries of discovery, the SNP microarray delivers efficient, high-quality genotyping data that powers many of today’s most impactful genomic investigations.